Mesenchymal-epithelial interaction regulates gastrointestinal tract development in mouse embryos.

Cell Rep

The State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China; Guangzhou Laboratory, Guangzhou, China. Electronic address:

Published: July 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

After gut tube patterning in early embryos, the cellular and molecular changes of developing stomach and intestine remain largely unknown. Here, combining single-cell RNA sequencing and spatial RNA sequencing, we construct a spatiotemporal transcriptomic landscape of the mouse stomach and intestine during embryonic days E9.5-E15.5. Several subpopulations are identified, including Lox stomach mesenchyme, Aldh1a3 small-intestinal mesenchyme, and Adamdec1 large-intestinal mesenchyme. The regionalization and heterogeneity of both the epithelium and the mesenchyme can be traced back to E9.5. The spatiotemporal distributions of cell clusters and the mesenchymal-epithelial interaction analysis indicate that a coordinated development of the epithelium and mesenchyme contribute to the stomach regionalization, intestine segmentation, and villus formation. Using the gut tube-derived organoids, we find that the cell fate of the foregut and hindgut can be switched by the regional niche factors, including fibroblast growth factors (FGFs) and retinoic acid (RA). This work lays a foundation for further dissection of the mechanisms governing this process.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2022.111053DOI Listing

Publication Analysis

Top Keywords

mesenchymal-epithelial interaction
8
stomach intestine
8
rna sequencing
8
epithelium mesenchyme
8
mesenchyme
5
interaction regulates
4
regulates gastrointestinal
4
gastrointestinal tract
4
tract development
4
development mouse
4

Similar Publications

3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth.

PLoS One

September 2025

Department of Biomedicine, Health and Life Convergence Sciences, BK21 Four, College of Pharmacy, Mokpo National University, Muan, Republic of Korea.

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths, remaining a significant challenge in terms of early detection, effective treatment, and improving patient survival rates. In this study, we investigated the anticancer mechanism of rubiarbonol B (Ru-B) and its derivative 3-O-acetylrubiarbonol B (ARu-B), a pentacyclic terpenoid in gefitinib (GEF)-sensitive and -resistant NSCLC HCC827 cells. Concentration- and time-dependent cytotoxicity was observed for both Ru-B and ARu-B.

View Article and Find Full Text PDF

EMT: from embryogenesis, through cancer progression, to the development of carcinosarcoma.

Differentiation

August 2025

Department of Anatomical Pathology, Hospital of Vimercate, Italy. Electronic address:

Epithelial cells are tightly connected to one another by intercellular junctions which prevent much of their motility, and have distinct apical-basal cell polarity, with their basal pole facing the basement membrane; they form mono- or multilayered sheet-like structures, and establish the borders of tissues and organs. In contrast, mesenchymal cells fill the spaces delimitated by other tissues, do not form stable contacts with other cells, are embedded within the extracellular matrix with which their entire surface interacts, and have definite locomotory capabilities. Epithelial-mesenchymal transition (EMT) occurs when an epithelium loses its distinguishing characteristics, and acquires mesenchymal traits.

View Article and Find Full Text PDF

Introduction: Baicalin has achieved the potential in the treatment of chronic pancreatitis (CP).To explore the potential of Baicalin on the induction of mesenchymal-epithelial transition (MET) in chronic pancreatitis.

Materials: To explore the causal association between CP and E-cadherin through bidirectional Mendelian randomization (MR).

View Article and Find Full Text PDF

The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review.

Transl Lung Cancer Res

July 2025

State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Background And Objective: Inhibitors of mesenchymal-epithelial transition () receptor serve as significant therapeutic agents in -driven non-small cell lung cancer (NSCLC). Among these, capmatinib has demonstrated particularly notable efficacy and safety. However, the mechanisms responsible for its benefit remain unclear.

View Article and Find Full Text PDF

Tepotinib is a highly selective, potent, mesenchymal-epithelial transition factor (MET) inhibitor, approved for the treatment of non-small cell lung cancer harboring MET exon 14 skipping alterations. This work aimed to investigate the potential for drug-drug interactions with strong inhibitors and inducers of both cytochrome P450 (CYP) 3A4/5 and P-glycoprotein (P-gp) with tepotinib. Two clinical studies were conducted to investigate the effect of the strong CYP3A4/P-gp inhibitor itraconazole (200 mg once daily) (NCT05203822) and the strong CYP3A4/P-gp inducer carbamazepine (titrated to 300 mg twice daily) (NCT05213481) on the pharmacokinetics of single dose tepotinib 500 mg (450 mg active moiety) in healthy participants.

View Article and Find Full Text PDF